瑞科生物-B发布中期业绩，股东应占亏损3.41亿元，同比扩大36.7%

Group 1 - The company reported a revenue of 10.899 million yuan for the first half of 2025, compared to no revenue in the same period last year [1] - The loss attributable to the parent company increased to 341 million yuan, representing a year-on-year increase of 36.7% [1] - The basic loss per share was 0.71 yuan [1] Group 2 - The increase in revenue was primarily due to income generated from granting intellectual property licenses during the period [1]